Warts Therapeutics Market to Exceed USD 2.5 billion by 2030, Garnering 3.0% CAGR Says, Transparency Market Research
September 25, 2023 05:37 ET
|
Transparency Market Research
Wilmington, Delaware, United States, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. - The warts therapeutics market was estimated to have acquired US$ 1.92 billion in 2018. It...
Warts Therapeutics Market Size to Outstrip $2,314.60Mn by 2028 Growth Projections at 3.4% CAGR During 2021 to 2028 COVID Impact and Global Analysis by TheInsightPartners.com
September 28, 2021 14:49 ET
|
The Insight Partners
New York, Sept. 29, 2021 (GLOBE NEWSWIRE) -- Warts Therapeutics Market: Key InsightsAccording to our new research study on “Warts Therapeutics Market to 2028 – Global Analysis and Forecast – by...
Genital Warts Pipeline: Insights into Novel Pipeline Therapies, Key Pharma Companies, Growth Prospects and Future Genital Warts Pipeline Landscape
July 26, 2021 20:00 ET
|
DelveInsight Business Research LLP
Los Angeles, July 26, 2021 (GLOBE NEWSWIRE) -- Genital Warts Pipeline: Insights into Novel Pipeline Therapies, Key Pharma Companies, Growth Prospects and Future Genital Warts Pipeline Landscape With...
Global Genital Warts Treatment Market to Surpass US$ 2,253.6 Million by 2028, Says Coherent Market Insights (CMI)
July 22, 2021 08:40 ET
|
CMI
SEATTLE, July 22, 2021 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, global genital warts treatment market is estimated to be valued at US$ 1,628.9 million in 2021 and is expected to...
Novan’s Drug Substance Demonstrates Inhibition of HPV-18 Virus Production
July 24, 2019 08:30 ET
|
Novan, Inc.
Preclinical data published in Antiviral ResearchStudy conducted by Drs. N.S. Banerjee, L.T. Chow and T.R. Broker at The University of Alabama at BirminghamFindings reinforce anti-viral mechanism of...
Novan Publication Supports Women’s Health Business Unit Initiative and Nitric Oxide’s Potential Against HPV-Associated Diseases
November 01, 2018 08:05 ET
|
Novan, Inc.
Data from SB206 Phase 2 clinical trial in external genital warts have been published in the Journal of Drugs in DermatologySB206 was efficacious and well tolerated in the trialAdvancement of the late...
Hemispherx to Present at the Marcum Microcap Conference in New York
May 20, 2015 08:30 ET
|
AIM ImmunoTech Inc.
PHILADELPHIA, May 20, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) will present at the Marcum Microcap Conference being held at the Grand Hyatt Hotel in New York City on Wednesday, May...
Hemispherx Biopharma Gains Broad Treatment Expansion for Alferon N Injection(R) in Argentina
March 04, 2013 08:00 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, March 4, 2013 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced that ANMAT (Administracion Nacional de Medicamentos, Alimentos y...